Department of Ophthalmology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
Ophthalmologica. 2013;229(3):168-72. doi: 10.1159/000346397. Epub 2013 Mar 16.
BACKGROUND/AIMS: To investigate the long-term effects of multiple intravitreal injections (IVTs) of ranibizumab (Lucentis) on intraocular pressure (IOP) in patients with neovascular age-related macular degeneration.
In 320 eyes, IOP measurements were performed at baseline prior to injection and compared with IOP measurements of the last visit. Correlations between mean IOP change and total number of IVTs, visual acuity or patient age were tested.
The mean IOP increase was 0.8 ± 3.1 mm Hg (p < 0.0001). Seven eyes showed final IOP values between 22 and 25 mm Hg. The mean follow-up was 22.7 ± 14.1 months. No further correlations between IOP change and number of IVTs, visual acuity or patient age have been found.
This study demonstrated a statistically significant IOP increase in patients treated with repeated injections of ranibizumab. However, IOP increase required no glaucoma treatment during the study. Therefore, repeated injections with ranibizumab can be considered safe with regard to long-term IOP changes in patients without ocular hypertension or glaucoma.
背景/目的：研究多次玻璃体内注射雷珠单抗（Lucentis）对新生血管性年龄相关性黄斑变性患者眼压（IOP）的长期影响。
在 320 只眼中，在注射前的基线和最后一次就诊时进行 IOP 测量，并对平均 IOP 变化与 IVT 总数、视力或患者年龄之间的相关性进行测试。
平均 IOP 升高 0.8 ± 3.1 mmHg（p < 0.0001）。7 只眼的最终 IOP 值在 22 至 25 mmHg 之间。平均随访时间为 22.7 ± 14.1 个月。未发现 IOP 变化与 IVT 总数、视力或患者年龄之间的进一步相关性。
本研究表明，接受雷珠单抗重复注射治疗的患者眼压有统计学显著升高。然而，在研究期间，眼压升高不需要进行青光眼治疗。因此，对于没有高血压或青光眼的患者，重复注射雷珠单抗可以被认为是安全的，不会导致长期眼压变化。
